Before Invest
Merck & Co., Inc. logo

Merck & Co., Inc.

MRK
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Unlock 40 quarters
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions 		Jun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023Mar 31, 2023Sep 30, 2022Jun 30, 2022Mar 31, 2022Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018Sep 30, 2017Jun 30, 2017Mar 31, 2017Sep 30, 2016Jun 30, 2016Mar 31, 2016Sep 30, 2015Jun 30, 2015Mar 31, 2015Sep 30, 2014Jun 30, 2014Mar 31, 2014Sep 30, 2013Jun 30, 2013Mar 31, 2013Sep 30, 2012Jun 30, 2012Mar 31, 2012Sep 30, 2011Jun 30, 2011Mar 31, 2011Sep 30, 2010Jun 30, 2010Mar 31, 2010Sep 30, 2009Jun 30, 2009
Sales
$ 16,607
$ 16,286
$ 17,276
$ 15,806
$ 15,529
$ 16,657
$ 16,112
$ 15,775
$ 15,962
$ 15,035
$ 14,487
$ 14,959
Costs, Expenses and Other
                                                    
Cost of sales
4,395
4,195
3,855
3,557
3,419
4,080
3,745
3,540
4,264
4,024
3,926
3,934
Selling, general and administrative
2,904
2,700
2,633
2,649
2,552
2,731
2,739
2,483
2,519
2,702
2,479
2,520
Research and development
9,741
12,592
4,234
4,048
3,621
5,862
3,500
3,992
3,307
13,321
4,276
4,399
Restructuring costs
151
195
47
560
69
56
80
123
126
151
67
94
Special, merger and acquisition-related charges
-
-
-
-
-
-
-
-
-
-
-
-
Equity income from affiliates
-
-
-
-
-
-
-
-
-
-
-
-
Other (income) expense, net
(99)
(138)
238
7
35
162
(42)
33
(126)
(172)
(89)
(429)
Total Costs, Expenses and Other
17,290
19,820
10,531
10,807
9,626
12,567
10,106
10,105
10,342
20,370
10,837
11,376
(Loss) Income Before Taxes
(683)
(3,534)
6,745
4,999
5,903
4,090
6,006
5,670
5,620
(5,335)
3,650
3,583
Income Tax Provision
654
709
958
571
818
929
545
903
870
637
825
330
Net (Loss) Income
(1,337)
(4,243)
5,787
4,428
5,085
3,161
5,461
4,767
4,750
(5,972)
2,825
-
Less: Net (Loss) Income Attributable to Noncontrolling Interests
(2)
(3)
2
1
6
4
6
5
5
3
4
5
Net Income from Continuing Operations
-
-
-
-
-
-
-
-
-
-
-
3,253
Net Income from Continuing Operations Attributable to Merck & Co., Inc.
-
-
-
-
-
-
-
-
-
-
-
3,248
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests
-
-
-
-
-
-
-
-
-
-
-
0
Net (Loss) Income Attributable to Merck & Co., Inc.
(1,335)
(4,240)
5,785
4,427
5,079
3,157
5,455
4,762
4,745
(5,975)
2,821
3,248
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
                                                    
Income from Continuing Operations (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
$ 1.28
Income from Discontinued Operations (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
0
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)
(0.54)
(1.72)
2.32
1.76
2.01
1.25
2.15
1.88
1.87
(2.35)
1.11
1.28
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
                                                    
Income from Continuing Operations (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
1.28
Income from Discontinued Operations (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
0
Preferred stock dividends
-
-
-
-
-
-
-
-
-
-
-
-
Net income available to common shareholders
-
-
-
-
-
-
-
-
-
-
-
-
(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)
(0.54)
(1.72)
2.32
1.76
2.01
1.24
2.14
1.87
1.86
(2.35)
1.11
1.28
Dividends Declared per Common Share (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
-